CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.13 USD | +13.00% |
|
+34.33% | -25.65% |
| May. 02 | CUREVAC : A missed opportunity |  |
| Apr. 26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11,713 | 5,645 | 1,072 | 854.1 | 650.8 | - | - |
| Enterprise Value (EV) 1 | 10,443 | 4,862 | 605 | 854.1 | 534 | 624.3 | 521.4 |
| P/E ratio | -67.7 x | -13.7 x | -4.27 x | -3.23 x | -3.37 x | -4.65 x | -6.97 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 240 x | 54.8 x | 15.9 x | 15.9 x | 11.2 x | 8.21 x | 5.26 x |
| EV / Revenue | 214 x | 47.2 x | 8.97 x | 15.9 x | 9.18 x | 7.88 x | 4.21 x |
| EV / EBITDA | -105 x | -6.38 x | -2.68 x | -3.41 x | -2.87 x | -4.84 x | -7.15 x |
| EV / FCF | 21.5 x | -5.67 x | -1.62 x | - | -2.35 x | -4.23 x | -8.08 x |
| FCF Yield | 4.65% | -17.6% | -61.8% | - | -42.5% | -23.6% | -12.4% |
| Price to Book | 12.3 x | 8.2 x | 2.06 x | - | 2.44 x | -4.15 x | -1.68 x |
| Nbr of stocks (in thousands) | 176,460 | 187,050 | 190,244 | 223,924 | 223,989 | - | - |
| Reference price 2 | 66.38 | 30.18 | 5.634 | 3.814 | 2.906 | 2.906 | 2.906 |
| Announcement Date | 4/15/21 | 4/28/22 | 4/25/23 | 4/24/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.42 | 48.9 | 103 | 67.42 | 53.8 | 58.14 | 79.27 | 123.8 |
| EBITDA 1 | - | -99.14 | -762.4 | -225.7 | -250.8 | -186.1 | -129 | -72.95 |
| EBIT 1 | - | -109.8 | -778.1 | -249.5 | -274.2 | -213.9 | -154.2 | -102.4 |
| Operating Margin | - | -224.54% | -755.53% | -370% | -509.67% | -367.86% | -194.59% | -82.7% |
| Earnings before Tax (EBT) 1 | - | -129.8 | -412.5 | -249.2 | -260 | -191.9 | -150.2 | -154.6 |
| Net income 1 | - | -129.1 | -411.7 | -249 | -260.2 | -184.1 | -128.6 | -79.85 |
| Net margin | - | -264.05% | -399.76% | -369.37% | -483.58% | -316.68% | -162.25% | -64.49% |
| EPS 2 | -137.4 | -0.9800 | -2.210 | -1.320 | -1.180 | -0.8611 | -0.6244 | -0.4166 |
| Free Cash Flow 1 | - | 486.1 | -857.4 | -374.2 | - | -227 | -147.5 | -64.5 |
| FCF margin | - | 994.02% | -832.46% | -555.03% | - | -390.45% | -186.08% | -52.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 4/29/20 | 4/15/21 | 4/28/22 | 4/25/23 | 4/24/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 29.36 | 41.22 | 24.4 | 20.1 | 11.2 | 11.69 | 7.129 | 7.579 | 16.5 | 22.6 | 12.89 | 12.89 | 16.33 | 13.09 | 3.545 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -143.1 | -371.4 | -15.27 | -60.3 | -52.4 | -121.5 | -60.36 | -71.8 | -54.04 | -88 | -57.4 | -54.68 | -48.72 | -51.11 | -64.8 |
| Operating Margin | -487.15% | -900.84% | -62.57% | -300% | -467.86% | -1,039.52% | -846.61% | -947.37% | -327.49% | -389.38% | -445.37% | -424.23% | -298.4% | -390.45% | -1,827.93% |
| Earnings before Tax (EBT) 1 | - | -4.559 | -15.2 | -57.6 | - | -128.8 | -57.42 | -67.39 | -48.7 | -86.5 | -55 | -52 | -51 | -52 | - |
| Net income 1 | - | -1.936 | -15.09 | -57.58 | - | -128.8 | -57.42 | -67.41 | -48.68 | -86.65 | -48.75 | -46.45 | -43.57 | -45.27 | - |
| Net margin | - | -4.7% | -61.86% | -286.49% | - | -1,101.75% | -805.43% | -889.48% | -295.04% | -383.42% | -378.23% | -360.36% | -266.9% | -345.89% | - |
| EPS 2 | - | - | -0.0800 | -0.3100 | -0.2500 | -0.6800 | -0.2700 | -0.3000 | -0.2200 | -0.3900 | -0.2400 | -0.2278 | -0.2147 | -0.2168 | -0.2737 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/17/21 | 4/28/22 | 5/25/22 | 8/18/22 | 11/16/22 | 4/25/23 | 5/30/23 | 8/17/23 | 11/14/23 | 4/24/24 | - | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,270 | 783 | 467 | - | 117 | 26.5 | 129 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 486 | -857 | -374 | - | -227 | -148 | -64.5 |
| ROE (net income / shareholders' equity) | - | -38.6% | -58.8% | -40.8% | - | -65.6% | -101% | -85.3% |
| ROA (Net income/ Total Assets) | - | - | -30.8% | -24.7% | - | -5.1% | -34% | -9.95% |
| Assets 1 | - | - | 1,335 | 1,009 | - | 3,610 | 378.2 | 802.8 |
| Book Value Per Share 2 | - | 5.380 | 3.680 | 2.740 | - | 1.190 | -0.7000 | -1.730 |
| Cash Flow per Share 2 | - | 3.950 | -3.940 | -1.510 | - | -1.040 | -0.7600 | -0.8600 |
| Capex 1 | - | 36.3 | 124 | 88 | - | 83.2 | 61.5 | 63.9 |
| Capex / Sales | - | 74.29% | 120.62% | 130.56% | - | 143.11% | 77.62% | 51.64% |
| Announcement Date | 4/29/20 | 4/15/21 | 4/28/22 | 4/25/23 | 4/24/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
2.906
EUR
Average target price
9.189
EUR
Spread / Average Target
+216.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.65% | 701M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +28.07% | 12.14B | |
| +0.17% | 12.15B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- CVAC Stock
- Financials CureVac N.V.
